Alpha Cognition (ACOG) Stock Fair Value Rises After Zunveyl Analyst Optimism
Alpha Cognition's (ACOG) fair value price target has increased from US$14.67 to US$16.75, attributed to analyst optimism surrounding its drug Zunveyl. Analysts highlight strong Q2 results, improving commercial execution, positive payer discussions, and Zunveyl's potential to address tolerability issues in Alzheimer's treatment. While bullish …